Vedolizumab as induction and maintenance therapy for ulcerative colitis

Clicks: 416
ID: 117041
2013
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Vedolizumab was more effective than placebo as induction and maintenance therapy for ulcerative colitis. (Funded by Millennium Pharmaceuticals; GEMINI 1 ClinicalTrials.gov number, NCT00783718.).
Reference Key
bg2013thevedolizumab Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Feagan BG;Rutgeerts P;Sands BE;Hanauer S;Colombel JF;Sandborn WJ;Van Assche G;Axler J;Kim HJ;Danese S;Fox I;Milch C;Sankoh S;Wyant T;Xu J;Parikh A; ;;
Journal The New England journal of medicine
Year 2013
DOI DOI not found
URL
https://www.pubmed.gov/23964932/
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine research support non-u.s. gov't adult female male aged middle aged Drug Administration Schedule Clinical Trial Phase III Randomized Controlled Trial Antibodies Monoclonal Double-Blind Method Multicenter Study Brian G Feagan Humanized / therapeutic use* Colitis Ulcerative / drug therapy* drug therapy combination induction chemotherapy immunosuppressive agents / therapeutic use maintenance chemotherapy glucocorticoids / therapeutic use humanized / adverse effects pmid:23964932 doi:10.1056/nejmoa1215734 paul rutgeerts gemini 1 study group humanized / pharmacokinetics integrins / antagonists & inhibitors integrins / immunology*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.